Previous 10 | Next 10 |
Key Highlights: Immuron FY19 revenue surged by 52% in North America, reaching $1.16M. In the USA, FY19 Travelan® sales exceeded the $1M AUD milestone for the first time and grew by +32% to $1.02M AUD. In May 2019, USA Travelan® sales achieved a record-breaking $182...
MELBOURNE, Australia, June 25, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company wishes to advise that two of its Directors, Mr Peter Anastasiou and Mr Daniel Pollock have recently acquired on-market 1,000,000 (25,000 ADS equivalent) ...
MELBOURNE, Australia, June 19, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of many gut mediated pathogens, today is please to rele...
Gainers: MoneyGram International (NASDAQ: MGI ) +106% . China Internet Nationwide Financial Services (NASDAQ: CIFS ) +33% . G1 Therapeutics (NASDAQ: GTHX ) +26% . SunPower Corporation (NASDAQ: SPWR ) +24% . Sundance Energy Australia (NASDAQ: SNDE ) +20% . Cortexyme (NASDAQ: CRTX...
Gainers: Coda Octopus Group (NASDAQ: CODA ) +40% . Mmtec (NASDAQ: MTC ) +30% . Red Robin Gourmet Burgers (NASDAQ: RRGB ) +29% . DryShips (NASDAQ: DRYS ) +24% . Cemtrex (NASDAQ: CETX ) +21% . Ruhnn Holding Limited (NASDAQ: RUHN ) +21% . RH (NYSE: RH ) +20% . Aeterna Zentaris (N...
Gainers: Synlogic (NASDAQ: SYBX ) +28% . Immuron (NASDAQ: IMRN ) +26% . B Communications (NASDAQ: BCOM ) +23% . Arcadia Biosciences (NASDAQ: RKDA ) +17% . Vuzix Corporation (NASDAQ: VUZI ) +14% . MagnaChip Semiconductor Corporation (NYSE: MX ) +13% . Osmotica Pharmaceuticals (N...
Thinly traded nano cap Immuron Limited ( IMRN +11.4% ) is up in early trade on the heels of encouraging results from a Shigella challenge study of in non-human primates aimed at assessing the effectiveness of Trevalen for preventing dysentery. More news on: Immuron Limited, Healthcar...
Key Highlights: Travelan ® shigellosis challenge studies in non-human primates successfully completed Travelan ® prevented clinical shigellosis (bacillary dysentery) in 75% of Travelan ® treated animals compared to placebo and demonstrated a significant...
MELBOURNE, Australia, May 30, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin therapeutics for the treatment of gut mediated diseases, today announced the closing of its ...
Gainers: Eltek (NASDAQ: ELTK ) +373% . Valeritas Holdings (NASDAQ: VLRX ) +40% . Soliton (NASDAQ: SOLY ) +34% . Technical Communications Corporation (NASDAQ: TCCO ) +30% . ReWalk Robotics (NASDAQ: RWLK ) +28% . Netshoes (Cayman) Limited (NYSE: NETS ) +19% . Cara Therapeutics (N...
News, Short Squeeze, Breakout and More Instantly...
Immuron Limited Company Name:
IMRN Stock Symbol:
NASDAQ Market:
Immuron Limited (IMRN) is expected to report for Q4 2023
MELBOURNE, Australia, May 03, 2024 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated bio...
MELBOURNE, Australia, May 03, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Stephen Anastasiou has resigned from his position as Non-Executive Director effective today to focus on his other bu...